The Cardiac Profile - IPD Package is an all-inclusive, in-patient hospital program meticulously designed for individuals requiring intensive cardiac assessment, stabilization, or post-procedure monitoring.
Tailored for patients with acute conditions like unstable angina, recent heart failure exacerbation, or those recovering from interventions such as angioplasty or bypass surgery, this package bundles essential services for a seamless care experience. It typically includes 24/7 nursing care in a cardiac ward, continuous telemetry monitoring, daily consultant visits, comprehensive laboratory work, advanced imaging (like Echocardiograms), and pharmacy support.
By consolidating these critical services, the IPD package ensures coordinated, high-quality care, promotes faster recovery, and provides peace of mind for patients and their families during a hospital stay.

The Cardiac Risk Marker Test is an advanced diagnostic panel designed to evaluate an individual's long-term likelihood of developing cardiovascular disease or experiencing a heart attack.
Unlike standard lipid profiles, this specialized test measures specific blood biomarkers—such as High-Sensitivity C-Reactive Protein (hs-CRP), Lipoprotein(a), Homocysteine, and Apolipoproteins—which detect hidden inflammation, plaque instability, and genetic predispositions to arterial blockage.
It is especially valuable for individuals with a family history of heart disease, normal cholesterol levels but unexplained cardiac events, or chronic conditions like diabetes. This crucial test enables early, targeted preventive interventions.

The Cardiolipin Antibody (ACL) - IgA Test is a specialized blood test used to detect IgA class antibodies directed against cardiolipin, a vital phospholipid found in cell membranes.
This test is primarily ordered to aid in the diagnosis of Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by abnormal blood clotting in arteries and veins, as well as recurrent pregnancy complications. While IgG and IgM are the most common isotypes tested, checking for IgA antibodies provides additional diagnostic value, especially in patients with clinical symptoms of APS who test negative for other markers. It helps physicians assess thrombotic risk accurately.

The Cardiolipin Antibody (ACL) - IgG Test is a crucial diagnostic blood test used to detect and quantify IgG class antibodies directed against cardiolipin, a key phospholipid found in cell membranes. This test is a primary tool in the diagnosis of Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by unexplained blood clotting (thrombosis) and pregnancy-related complications, such as recurrent miscarriages. Elevated levels of IgG-type ACL antibodies are strongly associated with the risk of these thrombotic events. The test is often ordered alongside IgM and IgA isotypes to provide a comprehensive profile for APS assessment and management.

The Cardiolipin Antibody (ACL) - IgM Test is a diagnostic blood test used to detect and measure the levels of IgM class antibodies directed against cardiolipin, a crucial phospholipid found in cell membranes. This test is a key component in the evaluation of Antiphospholipid Syndrome (APS), an autoimmune disorder associated with an increased risk of blood clots (thrombosis) in arteries and veins, as well as pregnancy complications like recurrent miscarriages. While IgG antibodies are more commonly associated with APS, testing for IgM provides additional diagnostic sensitivity, especially in acute phases of the condition. The result helps clinicians assess a patient’s risk profile.